@HTAFAC

Comité de Hipertensión Arterial. FAC

[Nicolas Renna, MD PhD ISHF FESC @nicolasrennamd]

Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. A broad level of general and specific recommendations. Great team work @ISHBP @saha_hipertens

[Nicolas Renna, MD PhD ISHF FESC @nicolasrennamd]

1 día de la Escuela de Verano de la Sociedad Argentina de HTA y European Society of Hypertension. Cordoba, Argentina @saha_hipertens @ESHypertension

[European Society of Cardiology Journals @ESC_Journals]

Improving #atherosclerosis risk prediction

#IMPROVE analysis of demographics, molecular markers & clinical assessment generates atherosclerosis endotypes for #PrecisionMedicine
https://t.co/Rj7CbLMS5x

@CVR_TomaszGuzik @DrMikeDrozd @glenpyle #AI #CardiovascularResearch

[Prof Alta Schutte @alta_schutte]

Proud of this paper as part of the management team of the Global Cardiovascular Risk consortium presented at #ESC2023 @georgeinstitute @UNSWMedicine - showing again that raised #bloodpressure to be the leading contributor to CV outcomes.

[FAC @fac_cardio]

"Simposio Cuyano de cardiometabolismo y Riesgo Cardiovascular"

🗓 29 y 30 de Septiembre
📍Merlo, San Luis

➕ Para más información: https://t.co/uyy0016dIo

#Simposio #Cardiologia #FAC

[European Society of Cardiology @escardio]

Early initiation of the sodium glucose co-transporter 2 (#SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in hospitalised patients with acute decompensated heart failure (ADHF).

#ESCCongress DICTATE-AHF trial - Early dapagliflozin initiation in acute heart failure.

[Prof Alta Schutte @alta_schutte]

Very interesting paper by @DaichiShimbo @Kazuomi_Kario and team - 3 days of home #bloodpressure are needed to id high BP.
Use of Different BP Thresholds to Reduce the Number of Home BP Monitoring Days Needed for Detecting Hypertension https://t.co/dLaEnAEDKX

[Gerardo Zapata, MD, MTFAC @GerardoOZapata]

Simposio Internacio al de la Sociedad de Cardiologia de Rosario. Un encuentro de gran nivel !!!

[Nicolas Renna, MD PhD ISHF FESC @nicolasrennamd]

Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation | Hypertension Research https://t.co/VTSNmC3VWc

[Daniel Piskorz @DanielPiskorz]

Muchas gracias Sociedad de Cardiología de Rosario por invitarme a participar del "Simposio Internacional SCR 2023 Investigación, Integración y Desarrollo". Felicitaciones Dr. Luis Keller, Comisión Directiva y secretarias, han puesto la vara muy muy alta!!!

[Nicolas Renna, MD PhD ISHF FESC @nicolasrennamd]

Agradezco mucho la invitación a la Sociedad de Cardiología de Rosario a esta excelente actividad rodeado de amigos y ciencia.

[International Society of Hypertension @ISHBP]

🎥 Watch: ISH President Prof Bryan Williams appears on the @escardio ESC TV in a segment on tough problems in the treatment of #hypertension.

Watch the interview (from 5min 39sec):
https://t.co/OMNVR5aAJv

[FAC @fac_cardio]

[REVISTA] Ya está disponible el Suplemento Nro. 3 de la Revista de FAC : “ANTAGONISTAS MINERALOCORTICOIDEOS EN EL CONTINUO CARDIO –NEFRO – METABÓLICO :ROL EMERGENTE DE LA FINERENONA “

➕ Para más información: https://t.co/ipISVrnMui

#Revista #FAC

[Daniel Piskorz @DanielPiskorz]

Antagonistas mineralocorticoideos en el continuo cardio-nefro-metabólico, nueva publicación de la Revista de la Federación Argentina de Cardiología. Disponible en https://t.co/tCcLmdbgqQ

[European Society of Cardiology @escardio]

Less than 1 month to go until #ESCCongress!

Register by 23:59 CEST 31 July to save ⏰ 💸 https://t.co/KSihiGoZmP

Join forces w/ thousands of your peers, experience ground-breaking research delivered by trailblazers, & network with the global community to accelerate your career

[Nicolas Renna, MD PhD ISHF FESC @nicolasrennamd]

Development and validation of a Medication Adherence Universal Questionnaire: the MAUQ - PubMed https://t.co/53iduIY6rb

[Sociedad Argentina de Hipertensión Arterial @saha_hipertens]

🔴 Les compartimos la Guía Práctica para el Manejo de la Hipertensión Arterial en las Farmacias 👇

Link💻: https://t.co/fzvE6CqkKE

#SAHA #HipertensiónArterial

[Nicolas Renna, MD PhD ISHF FESC @nicolasrennamd]

Roche enters partnership with Alnylam for hypertension therapy https://t.co/0XRbJLZuEQ

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

@DrWanpen presenting at what the future holds for HTN #ASPC2023
🫀 BP control poor during pandemic
🫀multiple causes for this
🫀role of #MRA (@AndrewJSauer 💜)
🫀newer drugs being studied: aprocitentan is phase 3 currently (PRECISION trial)
🫀siRNA technology or vaccine 💉 new

[NEJM @NEJM]

Angiotensinogen plays a key role in hypertension pathogenesis. Zilebesiran, an RNA interference therapeutic agent that inhibits angiotensinogen production, is being studied for hypertension treatment. New research findings are summarized in a short video. https://t.co/U2HS9BLfZX